Precipio Inc

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

Precipio Takes Major Steps Toward a Clean Balance Sheet

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting